AI Summary
The content explores the statistical methodology used in research on nivolumab and ipilimumab therapy for advanced hepatocellular carcinoma, highlighting the significance of the study's long-term follow-up data on efficacy and safety.
I commend the authors for their comprehensive study on nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib.1 This study significantly contributes to oncology, particularly in treating advanced HCC, providing valuable long-term follow-up on the efficacy and safety of this combination therapy.